Form 4: Supernus CEO Exercises Options, Sells Shares

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), engaged in transactions on October 2, 2025.
• Exercised employee stock options to acquire 2,267 shares of common stock at an exercise price of $25.30 per share.
• Subsequently sold 1,904 shares of common stock at a weighted average price of $48.06 per share, with prices ranging from $48.00 to $48.08.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 14, 2024.
• Following these transactions, Khattar directly owns 1,161,233 shares of common stock and indirectly owns 1,005,600 shares through the KBT Trust.
• He also holds 81,250 unexercised employee stock options.

Sentiment

Score: 6

Explanation: The CEO exercised options at a lower price and sold shares at a higher price, indicating a profitable transaction. The use of a 10b5-1 plan suggests the sale was pre-scheduled and not based on immediate, non-public information, which is generally viewed neutrally by the market. While insider selling can sometimes be a concern, the context of option exercise and a 10b5-1 plan makes it less impactful.

Positives

• The executive realized value from previously granted compensation by exercising options.
• The sale was executed at a significantly higher price ($48.06) than the exercise price ($25.30), indicating a profitable transaction for the insider.
• The transaction was conducted under a pre-arranged 10b5-1 plan, which suggests it was not based on immediate, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be interpreted in various ways, but the 10b5-1 plan provides transparency. The executive still retains a significant direct and indirect stake, maintaining alignment with shareholder interests.

Key Dates

Recommendation

The filing details a routine insider transaction involving the exercise of options and subsequent sale of a portion of those shares under a pre-arranged 10b5-1 plan. This type of transaction is common for executives managing their compensation and liquidity. It does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment thesis. The executive retains a substantial stake, suggesting continued alignment with shareholder interests. Therefore, a 'Hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Supernus Pharmaceuticals, SUPN, Jack Khattar, insider trading, Form 4, stock options, 10b5-1 plan, CEO, director, share sale